^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Uterine Corpus Leiomyosarcoma
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)

    Published date:
    07/19/2023
    Excerpt:
    NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS....In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51.
    DOI:
    10.1200/JCO.23.00402
    Trial ID:
    NCI protocol 10250